Top Markets
#1 EXOD EXOD +22.08%
#2 Geodnet Geodnet +17.63%
#3 Ontology Gas Ontology Gas +17.44%
#4 XPIN Network XPIN Network +17.03%
#5 Derive Derive +15.73%
#6 Status Status +13.62%
#7 Neiro Neiro +12.53%
#8 Pons Pons +12.37%
#9 Collect on Fanable Collect on Fanable +11.77%
#10 AUKI AUKI +9.94%
Coin of the day
EXOD EXOD
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Apollomics, Inc. Apollomics, Inc.

Apollomics, Inc.

APLM
Rang in Aktien #25238
Apollomics, Inc., a biotechnology enterprise established in 2015 and... Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Aktienkurs
$23.57
Zuletzt synchronisiert: 2026-08-20
Marktkapitalisierung
$51.76M
Veränderung (1 Tag)
-0.08%
Veränderung (1 Jahr)
289.59%
Land
US
Handel Apollomics, Inc. (APLM)

Kategorie

Healthcare
P/S-Verhältnis für Apollomics, Inc. (APLM)
P/S-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Apollomics, Inc. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/S-Verhältnis bei 0.
P/S-Verlauf für Apollomics, Inc. von 2026 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 -
US